Intermune Eyes Settlement Over Off-Label Marketing

Law360, New York (July 28, 2006, 12:00 AM EDT) -- Biotechnology company Intermune Inc. is preparing to pay as much as $30 million to settle allegations from federal prosecutors that it illegally promoted a drug for a use not approved by the U.S. Food and Drug Administration.

The U.S. Department of Justice began probing the Brisbane, Calif.-based company in 2004 after a former sales representative claimed she was fired for not taking part in off-label marketing—encouraging nonapproved uses of a drug.

The drug at the center of the controversy, Actimmune, currently has FDA approval for use...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.